Gland Pharma Q2 FY27 Revenue Up 23% to ₹18,336 Cr, PAT Jumps 58%
Gland Pharma reported Q2 FY27 results with revenue up 23% YoY to ₹18,336 crore and PAT up 58% YoY to ₹2,908 crore. CDMO business grew 31% and Critical Injectables grew 18%. Adjusted EBITDA increased 50% to ₹5,030 crore. The company will hold an earnings call on November 6th, 2026.
The announcement contains significant financial results with substantial year-on-year growth across key metrics, which is likely to have a high impact on investor sentiment and the company's stock.
The company reported strong year-on-year growth in revenue and profit after tax, along with significant increases in EBITDA and specific business segments. The management commentary also reflects a positive outlook.
Gland Pharma Limited announced its financial results for the second quarter ended September 30th, 2026, reporting a strong year-on-year growth. Revenue from operations increased by 23% to ₹18,336 crore, while Profit After Tax (PAT) saw a significant jump of 58% to ₹2,908 crore.
The company's performance was driven by robust execution across its businesses. The CDMO business grew by 31% year-on-year, contributing 45% of the total revenues, supported by expanding customer engagements and strategic partnerships. The Critical Injectables business contributed 55% of revenues and grew by 18% year-on-year.
Key financial highlights for Q2 FY27 include a 50% increase in adjusted EBITDA to ₹5,030 crore, with an adjusted EBITDA margin of 27%. R&D investments stood at ₹1,077 million, representing 6% of consolidated revenue. The company launched four new molecules in the USA during the quarter and filed eleven ANDAs, with ten approved.
Gland Pharma also announced an earnings call scheduled for November 6th, 2026, at 6:30 PM IST, to discuss the business performance.
What to do with a filing like this
Gland Pharma Limited filed this with the NSE as a statutory disclosure, categorised under quarterly results. It is a primary document, not a recommendation, and the desk marks it high impact, which is the band that most often changes something.
That call is the part a filing cannot make for you. On RealCase, SEBI-registered research analysts and investment advisers read announcements like this one and turn the ones that matter into actions inside their model portfolios: a change in weight, a hold, or nothing at all. You are not left working out which of the roughly 250 filings published each day needs a response. The portfolio you follow is updated when a filing actually warrants it, with the reason written down.
See the model portfoliosA plain-language summary of a public exchange filing by Gland Pharma Limited. Read the original for the full detail.